<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850680</url>
  </required_header>
  <id_info>
    <org_study_id>TDU13402</org_study_id>
    <secondary_id>U1111-1134-0048</secondary_id>
    <nct_id>NCT01850680</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the safety and tolerability of a single dose of subcutaneously administered
      sarilumab in Japanese patients with rheumatoid arthritis (RA) who are receiving concomitant
      treatment with methotrexate.

      Secondary Objective:

      To assess the pharmacokinetic profile of a single subcutaneous (SC) dose of sarilumab in
      Japanese RA patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total study duration per patient is up to 88 days

        1. Screening: 3 to 28 days

        2. Treatment: 1 day

        3. Follow-up: 57± 3 days after dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety parameters (adverse events, laboratory data, vital signs, and ECG)</measure>
    <time_frame>Up to 88 days or end-of-study (EoS)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the occurrence of anti-sarilumab antibodies</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the titer of anti-sarilumab antibodies</measure>
    <time_frame>Day 1, Day 15, Day 29, Day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - maximum concentration (Cmax)</measure>
    <time_frame>At each visit, up to 88 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - area under curve (AUC)</measure>
    <time_frame>At each visit, up to 88 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - time to maximum concentration (tmax)</measure>
    <time_frame>At each visit, up to 88 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sarilumab SAR153191 (REGN88)</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 2</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 3</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 4</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous</description>
    <arm_group_label>Placebo Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 2</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 4</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 3</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 1</arm_group_label>
    <arm_group_label>Placebo Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 2</arm_group_label>
    <arm_group_label>Placebo Dose 5</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 1</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 3</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191, REGN88) Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female Japanese who are 20 to 65 years of age

          2. Diagnosis of rheumatoid arthritis (RA) ≥ 3 months duration

          3. Treated for a minimum of 8 weeks with Methotrexate (MTX) and with a stable dose of MTX
             (6-16 mg/week) for a minimum of 4 weeks prior to the screening visit

        Exclusion criteria:

          1. Autoimmune or inflammatory systemic or localized joint disease other than RA

          2. Women of a positive pregnancy test

          3. Latent or active tuberculosis

          4. Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor
             (IL-6R) antagonist

          5. Treatment with anti-TNF agents, as follows:

               1. Etanercept: within 28 days prior to randomization

               2. Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to
                  randomization

          6. Received any live, attenuated vaccine within 3 months prior to the randomization visit
             (eg, varicella-zoster, oral polio, rubella vaccines)

          7. Significant concomitant illness such as, but not limited to, cardiovascular, renal,
             neurological, endocrinological, gastrointestinal, hepato-biliary, metabolic, pulmonary
             or lymphatic disease that would adversely affect the patient's participation in the
             study.

          8. Received surgery within 4 weeks prior to the screening visit or planned surgery during
             the study

          9. History of a systemic hypersensitivity reaction

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

